Achieve life sciences reports first quarter 2025 financial results and highlights updates in cytisinicline program

Reiterates planned submission of an nda for cytisinicline to fda in june 2025 company to host conference call at 8:30 am edt today, tuesday, may 13, 2025 seattle and vancouver, british columbia, may 13, 2025 (globe newswire) -- achieve life sciences, inc. (nasdaq: achv), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced its financial results for first quarter 2025 and confirmed that it plans to submit the upcoming new drug application (nda) for cytisinicline to the u.s. food and drug administration (fda) in june 2025. “the achieve team is fully committed to finalizing the nda for submission to the fda next month.
ACHV Ratings Summary
ACHV Quant Ranking